# Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/local-therapeutic-strategies-for-neurocutaneous-dysesthesia-from-capsaicin/ > **Published:** 2026-04-28T20:05:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:04:32-04:00 > **Clinical Summary:** Neurocutaneous dysesthesia (ND) is characterized by abnormal skin sensations such as pruritus or burning without an underlying skin condition. It is caused b... --- CED Clinical Relevance  #56Monitored Relevance Evidence Brief | CED ClinicComprehensive review identifies cannabinoids among local therapeutic options for neurocutaneous dysesthesia, a challenging nerve-related skin condition. [Neuropathic Pain](https://cedclinic.com/cannabis-for-pain-relief/)TopicalCannabinoidsDermatologyReview Comprehensive review identifies cannabinoids among local therapeutic options for neurocutaneous dysesthesia, a challenging nerve-related skin condition. What This Study Teaches Us This review establishes that neurocutaneous dysesthesia represents a distinct clinical entity requiring targeted local therapy when systemic treatments are unsuitable. The inclusion of cannabinoids alongside established agents like capsaicin and topical anesthetics suggests growing recognition of cannabinoid utility in peripheral neuropathic conditions. Why This Matters Neurocutaneous dysesthesia often leaves patients with limited treatment options, particularly when systemic medications are contraindicated. Having a comprehensive framework of local therapies, including cannabinoids, provides clinicians with evidence-based alternatives for this challenging condition. Study Snapshot Study Type Narrative Review Population Patients with neurocutaneous dysesthesia (abnormal skin sensations without underlying skin pathology) Intervention Local therapeutic modalities including cannabinoids among multiple topical agents Comparator Comparative overview of various local treatment approaches Primary Outcome Review of mechanisms of action and clinical applications of local treatments Key Finding Multiple local therapeutic options identified including cannabinoids as potential treatment for nerve-related skin symptoms Journal The Journal of dermatological treatment Year 2024 Clinical Bottom Line Local [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) represents a legitimate treatment consideration for neurocutaneous dysesthesia, positioned alongside established topical agents in the therapeutic armamentarium. This review validates the clinical rationale for topical cannabinoid use in nerve-related skin symptoms. What This Paper Does Not Show The abstract does not provide specific efficacy data, [dosing protocols](https://cedclinic.com/spasticity-clinical-guidelines-cannabis-utah/), or [comparative effectiveness](https://cedclinic.com/psychedelic-therapies-for-depression-efficacy-debate/) between cannabinoids and other local treatments. No information is given about which specific cannabinoids were reviewed or their relative clinical performance. Where This Paper Deserves Skepticism As a narrative review, this does not constitute primary evidence for cannabinoid efficacy. The quality and quantity of underlying studies supporting each treatment modality, including cannabinoids, cannot be assessed from this abstract alone. Dr. Caplan's Take I find it encouraging that cannabinoids are now being included in comprehensive dermatologic reviews alongside established therapies. However, the real clinical value depends on the underlying [evidence quality](https://cedclinic.com/cannabinoids-mental-health-systematic-review-evidence-insights/), which this review format doesn’t establish. I need to see the primary studies. What a Careful Reader Should Take Away This review legitimizes cannabinoids as a consideration for topical neuropathic skin conditions but represents expert opinion synthesis rather than primary efficacy evidence. Clinicians should view this as a framework for treatment approaches rather than definitive guidance. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Local%20therapeutic%20strategies%20for%20neurocutaneous%20dysesthesia%3A%20from%20capsaicin%20to%20cannabinoids.%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Flocal-therapeutic-strategies-for-neurocutaneous-dysesthesia-from-capsaicin%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Flocal-therapeutic-strategies-for-neurocutaneous-dysesthesia-from-capsaicin%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Local%20therapeutic%20strategies%20for%20neurocutaneous%20dysesthesia%3A%20from%20capsaicin%20to%20cannabinoids.%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Flocal-therapeutic-strategies-for-neurocutaneous-dysesthesia-from-capsaicin%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[What is neurocutaneous dysesthesia, and why is it hard to treat?](#What_is_neurocutaneous_dysesthesia_and_why_is_it_hard_to_treat) - [Which local treatments does the review discuss for this condition?](#Which_local_treatments_does_the_review_discuss_for_this_condition) - [Does this review show how well topical cannabinoids work or how to dose them?](#Does_this_review_show_how_well_topical_cannabinoids_work_or_how_to_dose_them) - [How strong is the evidence from this review for cannabinoid use?](#How_strong_is_the_evidence_from_this_review_for_cannabinoid_use) - [Related](#Related) ## FAQ ### What is neurocutaneous dysesthesia, and why is it hard to treat? Neurocutaneous dysesthesia is a nerve-related skin condition involving abnormal skin sensations without any underlying skin pathology. It often leaves patients with limited treatment options, particularly when systemic medications are contraindicated. The review describes it as a distinct clinical entity that requires targeted local therapy when systemic treatments are unsuitable. ### Which local treatments does the review discuss for this condition? The review covers multiple local therapeutic options, including established agents such as capsaicin and topical anesthetics, with cannabinoids included among them. It focuses on the mechanisms of action and clinical applications of these local treatments. The review was published in The Journal of Dermatological Treatment in 2024. ### Does this review show how well topical cannabinoids work or how to dose them? No. The abstract does not provide specific efficacy data, [dosing protocols](https://cedclinic.com/spasticity-clinical-guidelines-cannabis-utah/), or comparisons of effectiveness between cannabinoids and other local treatments. It also gives no information about which specific cannabinoids were reviewed or how they performed clinically relative to one another. ### How strong is the evidence from this review for cannabinoid use? It is limited. As a narrative review, it does not constitute primary evidence that cannabinoids are effective, and it represents a synthesis of expert opinion. The quality and quantity of the underlying studies supporting each treatment, including cannabinoids, cannot be assessed from the abstract alone, so it offers a framework rather than definitive guidance. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).